EUVIMEDOpdag EUVIMED
Crossref

The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center

Ashley J Crosby iD, Mariama Evans iD, Danielle L V Maracaja iD, Yara A Park iD, James F Howard iD, Matthew S Karafin iD

Journal of Clinical Apheresis · 2025

DOI: 10.1002/jca.70010 ↗

At a glance

Journal article in Journal of Clinical Apheresis, 2025. Written by Ashley J Crosby and 5 co-authors. Institution: Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA. Major MEDLINE topics: Myasthenia Gravis, Plasma Exchange, Single-Domain Antibodies. Cited 3 times so far (Crossref); 11 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies against proteins of the neuromuscular junction, such as the acetylcholine receptor (AChR). While therapeutic plasma exchange (TPE) has been a standard chronic therapy for patients with poorly controlled MG, new medications have recently been approved by the FDA for such patients. We report the impact of a new therapy, efgartigimod, on the number of therapeutic plasma exchanges performed on patients with generalized MG in our apheresis unit. A retrospective chart review was performed for patients with MG between 2018–2019 (pre‐efgartigimod) and 2022–2023 (post‐efgartigimod). We evaluated any changes between the two periods, including the total number of MG patients, the proportion of TPEs that were performed for MG, and the proportion of inpatient TPEs for MG. A statistically significant reduction ( p < 0.0001) was observed in the proportion of total TPE procedures for MG between the two time periods. In AChR‐antibody positive (AChR‐Ab +) patients who received both inpatient and outpatient procedures, there was a significant increase in the proportion of inpatient procedures post‐efgartigimod ( p = 0.0035). Our study demonstrated a decrease in the overall use of chronic TPE for MG over the 2‐year period following the release of efgartigimod. However, there will remain a role for TPE in the setting of acute MG flares, the inpatient setting, during pregnancy, and in those who do not tolerate the new medications.

Subjects

MeSH terms (MEDLINE)

Myasthenia GravisPlasma ExchangeSingle-Domain AntibodiesHumansRetrospective StudiesFemaleMaleTertiary Care CentersMiddle AgedAdultAutoantibodiesAgedReceptors, Cholinergic

Author keywords

efgartigimodmyasthenia gravisneonatal fc receptortherapeutic plasma exchange

Substances

AutoantibodiesReceptors, CholinergicSingle-Domain Antibodies

Authors and institutions

  • Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA.

ORCID profiles: Ashley J Crosby, Mariama Evans, Danielle L V Maracaja, Yara A Park, James F Howard, Matthew S Karafin

Cite

APA

Crosby, A. J., Evans, M., Maracaja, D. L. V., Park, Y. A., Howard, J. F., & Karafin, M. S. (2025). The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70010

Vancouver

Crosby AJ, Evans M, Maracaja DLV, Park YA, Howard JF, Karafin MS. The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center. Journal of Clinical Apheresis. 2025. doi:10.1002/jca.70010

BibTeX
@article{Crosby2025,
  author = {Crosby, Ashley J and Evans, Mariama and Maracaja, Danielle L V and Park, Yara A and Howard, James F and Karafin, Matthew S},
  title = {The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center},
  journal = {Journal of Clinical Apheresis},
  year = {2025},
  doi = {10.1002/jca.70010}
}
Start for free →